Literature DB >> 21132464

Alpinia galanga extracts downregulate interleukin-1β-induced matrix metalloproteinases expression in human synovial fibroblasts.

Peraphan Pothacharoen1, Kanyamas Choocheep, Thanyaluck Phitak, Wilart Pompimon, Prachya Kongtawelert.   

Abstract

Alpinia galanga has been used as alternative medicine for anti-rheumatic activities. However, the precise action of the extract on arthritic diseases is not yet fully understood. In this study, we investigated the effects of A. galanga extracts on the expression of genes involved in catabolic activities in an interleukin-1β (IL-1β)-induced human synovial fibroblast as an inflammatory model. Confluent primary human synovial fibroblasts were treated for 24 h with A. galanga hexane extracts in the presence of recombinant human IL-1β. MMPs in the culture medium were monitored by gelatin zymography. Total RNA was isolated from the cell lysate and analyzed via semi-quantitative RT-PCR. After treatment with A. galanga extracts, MMP-2 activity in the culture medium was significantly reduced. In addition, MMP-1, MMP-3, MMP-13, and Cox-2 expression were downregulated. These data suggest that the decrease of gene expression and production of MMPs in synovial fibroblasts against inflammatory stimuli could be due to the effects of the A. galanga extracts. Therefore, A. galanga extracts might be a promising therapeutic agent for arthritis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21132464     DOI: 10.1007/s11626-010-9375-2

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  41 in total

Review 1.  Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?

Authors:  P E Lipsky
Journal:  J Rheumatol Suppl       Date:  1999-04

Review 2.  Pathogenesis of rheumatoid arthritis: the role of synoviocytes.

Authors:  Y Yamanishi; G S Firestein
Journal:  Rheum Dis Clin North Am       Date:  2001-05       Impact factor: 2.670

Review 3.  A question of transformation: the synovial fibroblast in rheumatoid arthritis.

Authors:  Laurie S Davis
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  Gelatinases A and B.

Authors:  G Murphy; T Crabbe
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

5.  Expression of IL-1 genes in human and bovine chondrocytes: a mechanism for autocrine control of cartilage matrix degradation.

Authors:  F Ollivierre; U Gubler; C A Towle; C Laurencin; B V Treadwell
Journal:  Biochem Biophys Res Commun       Date:  1986-12-30       Impact factor: 3.575

Review 6.  Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis--targetting gelatinase A activation.

Authors:  C Jackson; M Nguyen; J Arkell; P Sambrook
Journal:  Inflamm Res       Date:  2001-04       Impact factor: 4.575

7.  Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis.

Authors:  C S Westhoff; D Freudiger; P Petrow; C Seyfert; J Zacher; J Kriegsmann; T Pap; S Gay; P Stiehl; E Gromnica-Ihle; D Wernicke
Journal:  Arthritis Rheum       Date:  1999-07

Review 8.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

9.  Elevated plasma stromelysin levels in arthritis.

Authors:  S Zucker; R M Lysik; M H Zarrabi; R A Greenwald; B Gruber; S P Tickle; T S Baker; A J Docherty
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

Review 10.  Apoptosis as a therapeutic tool in rheumatoid arthritis.

Authors:  Richard M Pope
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.